Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: A north American perspective

Anthracycline agents are used for treatment of acute myeloid leukemia (AML) but may cause late‐onset cardiomyopathy. Current frontline therapy for AML in North America, as reflected in the approach of the Children's Oncology Group (COG) and other pediatric consortia, is adapted from the anthracyline‐intensive Medical Research Council (MRC) regimen. The purpose of this study was to describe early post‐treatment cardiac function as a potential indicator of acute and long‐term risk associated with this approach.